Preclinical

The word preclinical covers all research carried out before a compound is first given to humans. In regulatory usage it refers to everything a sponsor assembles before filing an Investigational New Drug (IND) application: selectivity screening and pharmacology in vitro, efficacy testing in animal disease models, pharmacokinetics and ADME work, safety pharmacology on cardiovascular, respiratory and central nervous system endpoints, and toxicology under GLP, typically in two species.

Why the term matters here

Nearly all peptides sold for research are at this stage, and many are at its very beginning — a handful of published rodent studies and cell experiments, with no formal GLP toxicology and no IND. Stating that "preclinical evidence exists" is thus accurate and honest, and it is considerably weaker than stating that human trial data exist. Attrition figures make the gap tangible: most compounds that looked promising in animals later fall short on efficacy or safety in human testing, and the step from rodent model to human is widely acknowledged as the bottleneck.

This shapes how findings should be cited: always name the species, the model and what kind of study it was. A sentence beginning "in rats, researchers found" is not equivalent to one citing "phase 2 trial results", and neither can back up claims about human outcomes with research-grade material — which we supply strictly for laboratory work.

Related terms and material

phase 1/2/3 trial · FDA-approved vs research-grade. Reference material: all research products.